February 4, 2008 - NextBio (www.nextbio.com) today announced that it has renewed and expanded its licensing agreement with the Burnham Institute for Medical Research in San Diego, California, for the use of NextBio's innovative life science search engine. Under the agreement, every scientist at the Burnham Institute will gain access to the NextBio life science search engine, enabling them to search data from both public and proprietary sources to bring their own experimental results within the context of other research findings worldwide.

"In one of our key studies, we used the NextBio search engine to interpret the gene expression changes between adenoma tumors associated with two distinct genotypes," said Robert Oshima, Ph.D., Tumor Development Program co-Director and Professor at the Burnham Institute. "Instead of manually evaluating hundreds of genes through literature, we were able to quickly search for conditions with similar biological changes using a combined collection of public studies. NextBio has proven to be valuable in interpreting gene expression changes in our experiments."

"The ability of Burnham scientists to utilize huge quantities of public and internal experimental data in an easy way is fundamental to our research efforts," commented Craig Hauser, Ph.D., Cancer Center Associate Director at Burnham Institute for Medical Research. "NextBio's life science search engine enables our researchers and clinicians to generate and validate new hypotheses using information from thousands of large-scale experimental studies."

"We are delighted to see the Burnham Institute provide access to NextBio for its entire research staff and believe that NextBio will become an integral part of their daily research," said Ilya Kupershmidt, NextBio's Vice President of Product Management. "We are very pleased that Burnham, as one of our pioneering customers, has renewed and expanded its license to use NextBio."

NextBio is a life science search engine that enables researchers and clinicians to access and understand the world's life sciences information to find important new correlations, make discoveries, and generate hypotheses as never before. NextBio is implemented as a "Software as a Service" (SaaS) model that permits users to use its search engine directly via the web and internal client sites through the NextBio Application Programming Interface (API). NextBio is used daily by some of the world's leading research enterprises, including Stanford University, UC Davis, Scripps Research Institute, Johnson & Johnson, Celgene and Genzyme.

— Innovative Search Engine Helps Drug Discoverers Understand Research Data in the Context of Other Findings —

January 28, 2008 - NextBio (www.nextbio.com) today announced that it has entered into a major licensing agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. for use of NextBio's innovative life sciences search engine and collaboration platform. NextBio is being used by researchers and clinicians at Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Tibotec Therapeutics and Centocor.

"This agreement is a milestone for NextBio," said Saeid Akhtari, NextBio's President and Chief Executive Officer. "Johnson & Johnson is one of the world's most successful and innovative companies. We are very pleased to be working with their outstanding team in making NextBio an integral part of their internal R&D efforts. We are seeing major validation of our Software as a Service (SaaS) model as leading enterprises securely integrate and search their internal data using our innovative search engine."

"We are seeing tremendous demand within the industry for the ability to intelligently search across vast quantities of internal and public biological and chemical data in real time – a concept pioneered by NextBio," commented Ilya Kupershmidt, NextBio's Vice President of Product Management. "Johnson & Johnson joins a growing number of premier research institutions and companies who are using NextBio daily in their research efforts, including Stanford University, UC Davis, Scripps Research Institute, Celgene and Genzyme."

NextBio is a search engine that enables researchers and clinicians to access and understand the world's life sciences information to find important new correlations, make discoveries, and generate hypotheses as never before. NextBio is implemented via a Software as a Service (SaaS) model that users can search directly or via internal company sites through the NextBio Application Programming Interface (API).

Cupertino, CA, October 9, 2007 - NextBio (www.nextbio.com) announced today that Dr. B. Michael Silber, former Senior Vice President and Site Head of Preclinical R&D (Safety & Technical Sciences) at Roche Pharmaceuticals, has joined the company's Scientific Advisory Board.

"Dr. Silber has been a major figure in the pharmaceutical industry for more than twenty years. His leadership has been essential in the successful development of a variety of innovative new medicines that are widely used in the world today," stated NextBio co-founder and CEO Saeid Akhtari. "We are honored that Michael Silber has joined the NextBio team. His experience and commitment to scientific excellence will be vital as we move forward."

"I am delighted to join NextBio's Scientific Advisory Board," stated Dr. Silber. "They have a clear vision of how to help scientists and clinicians effectively use the vast amount of life sciences data that is now available. By putting this information at their fingertips, NextBio is enabling every scientist and clinician to greatly increase the pace of scientific discovery."

Prior to joining NextBio, Dr. Silber held senior executive positions in several of the world's leading Pharma/Biotech companies, including most recently as Senior Vice President and Site Head of Preclinical R&D (Safety & Technical Sciences) at Roche Pharmaceuticals. He has experience developing innovative new medicines in major diseases and has expertise in root cause analysis of R&D attrition/success. Dr. Silber has published over 120 research articles, book chapters, and abstracts, and is a member of the editorial boards of six journals. He has also held other key positions, including Vice President of R&D at J&J/ALZA, Director of Genomic and Proteomic Sciences at Pfizer Research, Senior Director and Division Head of Pharmacology and Toxicology at Cetus (Novartis), Director and Head of Drug Metabolism at Lederle (Wyeth), and Assistant Professor, University of Washington School of Medicine and Pharmacy. Dr. Silber has a PhD in Pharmaceutical Chemistry and Pharmacology from the University of California, San Francisco.

Cupertino, CA, July 11, 2007 - NextBio (www.nextbio.com) today announced that it has released a new version of its search engine for life sciences data with chemistry-enabled search features. The latest update of NextBio contains powerful search capabilities and content designed to help researchers and clinicians explore high-throughput and high-content screening data.

"We are very impressed with the richness of content and ease of use that the latest version of NextBio provides our researchers", stated Dr. Nick Tsinoremas, Senior Director of Informatics at Scripps Florida. "NextBio enables us to cover key areas of importance to Scripps - linking genomic and chemical information under a single, powerful search interface. In addition, NextBio has become our central web-based repository for internal studies, allowing real-time collaboration."

"At NextBio, we are focused on building the most versatile and user-friendly search and collaboration engine for the life sciences community," said Ilya Kupershmidt, Vice President of Product Management at NextBio. "The latest release with chemistry-enabled features is a strong testament to our commitment to systematically incorporate the world's diverse large-scale data into NextBio. This release is particularly important since it demonstrates the capabilities of NextBio's search technology beyond commonly used genomic platforms."

NextBio enables scientists, researchers and clinicians to:

• Search and correlate information across data types, domains and species
• Manage, search and correlate internal biological and chemical data
• Share data through a secure access-controlled environment
• Utilize an extensive biomedical ontology for data consistency

Cupertino, CA, June 26, 2007 - NextBio (www.nextbio.com) today announced that it has entered into a licensing agreement with Genzyme for use of its innovative life sciences data search engine and collaboration platform.

"We were very impressed with NextBio's powerful search and data correlation features, quality and breadth of content and attention to detail in critical areas such as usability, security and scalability," said Dr. Steve Madden, Director of Functional Genomics at Genzyme. "We believe that NextBio is a valuable resource that empowers our researchers to do better science and generate more focused hypotheses."

"We are very pleased that Genzyme has chosen NextBio as a critical resource," said Saeid Akhtari, co-founder and CEO of NextBio. "Genzyme's selection of NextBio is a testament to our ability to serve vital needs of the pharmaceutical and biotechnology industries. NextBio directly addresses the urgent research and productivity demands of life scientists and researchers who need to gain a greater understanding of the biological relevance of their high-throughput data."

NextBio is a life sciences data search engine and community data sharing platform that introduces the web 2.0 paradigm of instant access, user-generated content and collaboration to life scientists and clinicians worldwide. Launched in 2006, NextBio's search engine has rapidly gained adoption among users in leading academic institutes and pharmaceutical/ biotechnology companies who have endorsed its visionary approach to data search and sharing.

Cupertino, CA, June 6, 2007 - NextBio (www.nextbio.com), a Cupertino-based company that has developed the first search engine for life sciences data, today announced the closing of a $7 million "Series B" financing led by Newbury Ventures (www.newburyven.com), with participation by existing investors.

The new funds will be used to further expand NextBio's industry-leading content, scale its technology infrastructure to handle millions of queries, and build its community collaboration and data sharing features. Bruce Bauer, Senior Managing Director of Newbury Ventures, will join NextBio's Board of Directors.

"We believe there is a tremendous market opportunity for a search engine that fundamentally changes the way life science researchers find and share information," stated Bruce Bauer of Newbury Ventures. "NextBio's outstanding customer traction and feedback makes this an especially exciting investment for us. We believe that NextBio has the seasoned team, technology, and long-term vision to transform an entire industry."

"We are excited to bring on board an experienced investor that shares our passion for revolutionizing life sciences research and drug development," said Saeid Akhtari, NextBio's co-founder and CEO. "We will utilize this significant capital infusion to accelerate our innovation, expand our content, and rapidly globalize adoption of the NextBio search and collaboration engine."

NextBio is a life sciences data search engine and community data sharing platform that introduces the web 2.0 paradigm of instant access, user-generated content and collaboration to life scientists and clinicians worldwide. Launched just eight months ago, NextBio's search engine has rapidly gained traction with users in over 60 academic institutes and pharmaceutical/ biotechnology companies that have endorsed its visionary approach to data search and sharing.

About NextBio

NextBio is the world's first data search and collaboration engine for life scientists and clinicians. Founded by a team of visionary innovators, NextBio addresses a fundamental need within R&D to effectively leverage vast quantities of internal and public life sciences information by connecting millions of researchers and clinicians through its search and share engine. NextBio's value in improving research efficiency and effectiveness has already been validated at the world's leading research organizations. For more information, visit www.nextbio.com.

About Newbury

Newbury Ventures is an international venture capital group focused on investing in and growing entrepreneurial companies in the technology, communications, information technology, and health care industries. Founded in 1992, Newbury is known for its insight, integrity and global approach to the business of venture capital, and has successfully managed investments of over $500 million in North America and Europe. Newbury's partners have financed well over 100 successful emerging growth technology companies, including Okena, Netro, Precise Software, Corvis/Algety, nCipher, and ACC. Newbury has offices in Redwood Shores, California; Ottawa, Canada; and Paris, France.
www.newburyven.com

Cupertino, CA, March 6, 2007 - NextBio (www.nextbio.com) today announced that Dr. David L. Barker, recently retired Chief Scientific Officer of Illumina, Inc. (NASDAQ:ILMN), has joined its Board of Directors. In his role as director, Dr. Barker will help define the strategic goals of the company. Dr. Barker is the latest addition to a team of directors and advisors that includes leaders in science and medicine such as Dr. Leroy Hood of the Institute for Systems Biology and Dr. Ron Davis of the Stanford Genome Technology Center.

"Dr. Barker's addition to our team provides tremendous validation of NextBio's paradigm of empowering life scientists and clinicians everywhere with our data search engine," said NextBio co-founder and CEO Saeid Akhtari. "We are honored and pleased that Dr. Barker shares our vision for the Company and welcome him to our Board."

"I am truly excited about NextBio and its future as a valuable resource for researchers and clinicians," stated Dr. Barker. "What NextBio has created is a remarkable search engine and content knowledgebase that seamlessly integrates heterogeneous data from all life science sources, changing the way researchers and clinicians work."

"Dr. Barker's addition to our team further reinforces our mission to advance the way life sciences research is conducted," said Dr. Mostafa Ronaghi, co-founder of NextBio.

Prior to joining NextBio, Dr. Barker was Vice President and Chief Scientific Officer at Illumina, Inc., in San Diego, California, which he joined in March 2000. Illumina is one of the leading companies in the life sciences space and an innovator in the BeadArray chips used for genotyping. From 1998 to 2000, Dr. Barker served as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.

Cupertino, CA, January 31, 2007 - NextBio (www.nextbio.com) today announced new features and content that give researchers and clinicians the ability to explore the world's largest resource of experimental study results with more ease and security using the NextBio data search, store and share engine. Saeid Akhtari, CEO and cofounder of NextBio, announced:

"We are excited to provide our users with the opportunity to search much more data across new species as we continue to organize and make accessible a new world of life sciences information to our users. Our close relationship with our pilot customers has enabled us to respond quickly to our users' needs and requirements. The new features enable researchers and clinicians to improve productivity by having more immediate access to relevant study results using our revolutionary search engine."

The new release of NextBio provides major content updates in the areas of clinical genomics, stem cells and development, as well as compound and tissue profiling. Among the new features are an improved user interface and query capabilities and an infrastructure to securely store and manage proprietary internal data from individual users and organizations.

"Our most recent updates represent a significant milestone for NextBio and major enhancements for our users. The feedback has been tremendous, and we are working hard to continue our innovations," commented Ilya Kupershmidt, cofounder of NextBio and VP of Product Management.

Overview of NextBio Enhancements:

The NextBio UI has been upgraded to give users better performance and experience when dealing with large sets of data. Additional improvements include new visualization features for queries and offering users new and powerful ways of exploring their findings.

NextBio now includes thousands of new study results across diverse disease areas, with an emphasis on clinical genomics, compound and tissue profiling studies, as well as stem cells and development. With this latest update, NextBio provides researchers and clinicians with the largest resource of high quality large-scale study results in the world.

NextBio now offers a fully transparent environment to explore and correlate internal and public data from human, rat, mouse, worm, fly and yeast genomes. For example, researchers can seamlessly correlate information from genetic studies in drosophila with human disease signatures, or find relationships between yeast drug targets and tissue-specific profiles in humans.

NextBio offers fully secure on-demand access to its software via the internet. Each customer will now access their own private account where internal data can be securely stored, managed and explored. This major development places NextBio at the cutting edge of the latest technology and minimizes maintenance and support issues for our customers. NextBio can also be deployed behind the client's firewall.

In addition, NextBio is pleased to announce a series of webcasts for customers and partners to showcase the latest features of its search engine. The initial webcast in the series "What's New in NextBio" takes place on Tuesday, February 6, 2007 at 10:00 am PST/ 1:00 pm EST.

To register for this webcast and to receive details of the NextBio webcast program, visit http://www.nextbio.com/news_events.html.

Cupertino, CA, October 24, 2006 - NextBio (http://www.nextbio.com), whose innovative knowledge-based discovery platform introduces a new paradigm in the management and interpretation of biological and clinical information, today announced the founding members of its Scientific Advisory Board (SAB): Dr. Leroy Hood, Dr. Ronald Davis, Dr. Mostafa Ronaghi, Dr. Keith Joho, Dr. Nick Tsinoremas and Dr. Saeed Tavazoie. The SAB, which comprises a broad base of scientific experts from academic and industry research settings, will offer guidance to NextBio management in ensuring the biological and clinical relevance of future product development.

Leroy Hood, M.D., Ph.D.: "One of the challenges of the new systems biology paradigm is how to enable scientists to easily sift through vast quantities of large-scale information that cannot be easily captured in published literature and, at the same time, organize and integrate different types of data in ways that are conducive to computational analysis and modeling. NextBio has made striking progress toward that objective."

Dr. Hood is President and cofounder of the Institute for Systems Biology in Seattle, Washington. He has been at the forefront of scientific discovery and technological research for more than 35 years. Dr. Hood has published more than 600 peer-reviewed papers, received 12 patents, cofounded nearly a dozen companies and was awarded the 2002 Kyoto Prize in Advanced Technology for his outstanding contributions to biotechnology and medical technology.

Ronald Davis, Ph.D.: "What NextBio is doing for biological information is analogous to what happened when we went from northern blots to microarrays."

Dr. Davis is the Director of the Stanford Genome Technology Center and Professor of Biochemistry and Genetics at the Stanford University School of Medicine. He is a world-renowned researcher in the areas of genomics and high-throughput biochemical techniques. He pioneered many of the early techniques using recombinant DNA and helped conceive of novel methods for genetic linkage analysis. Professor Davis has also been involved in the spin-off of multiple start-up companies in the area of genomics from his laboratory at Stanford.

Mostafa Ronaghi, Ph.D.: "The systematic collection of information provides the backbone of biology. Any one study is just a piece of the puzzle in an ocean of pieces. NextBio connects the pieces of the puzzle, revealing new insights into biological systems."

Dr. Ronaghi is cofounder of NextBio and an experienced entrepreneur. He cofounded Pyrosequencing in 1997 (renamed Biotage in 2003) and ParAllele BioScience in 2001 (sold to Affymetrix). He is currently a principal investigator at Stanford University focusing on developing novel tools for molecular diagnostics. Dr. Ronaghi holds more than 20 pending and issued patents and has written more than 50 peer-reviewed publications in journals and books.

Keith Joho, Ph.D.: "The research community has been looking for a solution like NextBio for the last ten years. It is going to have a huge impact on productivity."

Dr. Joho is a leader in the bioinformatics community having held senior management positions in bioinformatics at Ingenuity Systems, SurroMed, Abgenix, Roche BioScience and SUGEN. He has also served on the faculty of the Department of Biochemistry and Molecular Biology at the Louisiana State University Medical Center. He is currently a consultant focusing on informatics challenges in biopharmaceutical research.

Nick Tsinoremas, Ph.D.: "NextBio is liberating for bench scientists. It gives them an intuitive way to query across private and curated public data without having to be bioinformatics experts."

Dr. Tsinoremas is a Senior Director of Informatics at Scripps Florida where he oversees data analysis systems ranging from statistical genetics and data mining to chemo-informatics and sequence-based analysis. Previously, Dr. Tsinoremas held senior positions in computational genomics and bioinformatics at Rosetta/Merck, DoubleTwist, Incyte Genomics and Progenitor. Dr. Tsinoremas' original research includes light-regulated gene expression and circadian rhythms.

Saeed Tavazoie, Ph.D.: "NextBio's intuitive platform allows the biologist to navigate through the astronomical number of hypotheses that modern datasets make possible. This is the first step in turning mountains of data into new discoveries."

Dr. Tavazoie is a professor in the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University. He has done pioneering research in the areas of computational biology and functional genomics. Professor Tavazoie has broad cross-disciplinary expertise in biophysics, molecular biology, genomics, computational biology and medicine. His current research is aimed at developing new conceptual frameworks for extracting biological understanding from large experimental datasets.

"NextBio's goal is to remove informatics barriers that have impeded biopharmaceutical research for years, and that goal is founded on a philosophy of innovation," said Saeid Akhtari, president, CEO and cofounder of NextBio. "This is clearly a philosophy we share with each member of our Scientific Advisory Board. We are honored to be working with this distinguished group of scientists."

October 17, 2006, Cupertino, CA - NextBio (http://www.nextbio.com) today announced the general availability of its first-of-a-kind, knowledge-based discovery platform. For nearly a year, scientists at leading research institutions have been using NextBio's platform in diverse therapeutic areas to generate new hypotheses and advance research discovery. NextBio enables scientists to make novel discoveries by leveraging information across the entire organization and across an expanding reference database of carefully curated, large-scale public studies. With an interface that's as easy to use as the most popular internet search engine, NextBio empowers any scientist to formulate complex questions across different assay platforms, data types, therapeutic areas and organisms to gain valuable scientific and clinical insights.

Among early access users are research and clinical scientists at Scripps Florida, UC Davis, Stanford University, Princeton University, Yale University, University of Florida, the Institute for Systems Biology, Genentech, and Burnham Institute, as well as other commercial and academic organizations. With NextBio, scientists can quickly associate disease states with specific pathways and genes, identify compounds with a particular mechanism of action and profile target activity across a collection of tissue signatures.

"NextBio gives researchers a view of all the different experiments in its repository at once, so they're able to come up with questions they wouldn't have thought of before", said Dr. Nick Tsinoremas, senior director of informatics at Scripps Florida. "NextBio is liberating for bench scientists because it empowers them with intuitive querying capabilities across multiple data sets without the need for bioinformatics expertise."

"With NextBio, I can accomplish in a few minutes and with just a few clicks what previously took me months to do, and that's if I could actually find all of the study results and bring them into one platform", said Dr. Frank Sharp, Professor, UC Davis M.I.N.D. Institute. "I use NextBio to narrow down my experimental hypotheses before getting into the wet lab, and again to interpret my study results in the context of the large repository of information NextBio contains."

NextBio was founded in 2004 by former executives from Silicon Genetics and ParAllele BioScience. "For years, biopharmaceutical organizations have struggled with how to develop improved therapies from knowledge buried in the vast quantities of data generated in their own research labs and available through public sources", said Saeid Akhtari, cofounder, president and CEO of NextBio. "NextBio addresses that challenge with an innovative platform that is immediately accessible to and facilitates novel insights for bench scientists, clinicians and bioinformatics experts alike."

NextBio improves the research effectiveness and efficiency of individual researchers, and automatically scales to provide productivity gains throughout the enterprise. NextBio's flexible repository integrates a wide variety of assay data types, facilitating collaboration among previously segregated research domains. Organizations can reuse and maximize the scientific value of information across projects, therapeutic areas and research silos, thereby increasing their return on investment in "omics" technologies.

The NextBio platform is offered exclusively by NextBio.